Form 8-K AbbVie Inc. For: Nov 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
November 5, 2018 8:47 AM ESTBMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a Underperform rating.
The analyst commented, "3Q18 was fine, but not great; particularly the Imbruvica beat. The market is ignoring management's long-term guidance, and signals of... More
